Earnings Outlook For Verrica Pharmaceuticals
Portfolio Pulse from Benzinga Insights
Verrica Pharmaceuticals (NASDAQ:VRCA) is scheduled to release its quarterly earnings report on Thursday, 2024-02-29, with analysts expecting an EPS of $-0.53. The company's past earnings performance shows a mixed impact on its stock price, with the last quarter's beat resulting in a 4.21% drop. Shares are currently trading at $5.67, down 24.18% over the last year. Investors will be keenly watching for not just the earnings beat but also the forward guidance provided by the company.
February 28, 2024 | 7:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Verrica Pharmaceuticals is expected to report an EPS of $-0.53 for the quarter. Historical data shows mixed reactions to past earnings, with the stock currently down 24.18% over the last year. Investors will focus on the earnings outcome and future guidance.
Given VRCA's mixed historical earnings performance and the current negative year-to-date return, the upcoming earnings report and guidance could have a neutral to slightly negative impact. The anticipation of the report might cause some volatility, but the actual impact will heavily depend on whether VRCA meets or exceeds the EPS expectations and the nature of the forward guidance provided.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100